Track 3 Speakers
Jacquelyn Boudjeda has been with the National Cancer Institute in the Office of Grants Administration since 2008. She has been an SBIR/STTR Program contact for the past two years and thoroughly enjoys working with the small business community. Her knowledge of SBIR/STTR awards keeps her in high demand to participate in various NIH committees and focus groups. Boudjeda has also been an active member of the Annual NIH SBIR/STTR Conference Planning Committee.
Kristopher Bough, M.S., Ph.D.
Kristopher Bough, Ph.D., is a neuroscientist and pharmacologist with a background in ‘top-down’ translation. During his career in academia, Bough developed an animal model for an unexplored therapy of epilepsy and, subsequently, employed a variety of approaches (e.g., electrophysiology, microarrays, electron microscopy) to investigate its underlying mechanisms of action.
In 2005, he began his career in the government within the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research, where he served as a pharmacologist before moving to the NIH National Institute on Drug Abuse’s Division of Pharmacotherapies and Medical Consequences in 2008. There he oversaw a clinical portfolio of Phase I / II clinical trials, primarily aimed at the development of novel treatments for nicotine- and cocaine addiction. Since joining NIH, Bough has helped manage NIDA’s SBIR program on both the divisional- and institute-level and served as an annual reviewer for the Commercialization Assistance Program. Bough’s presentation will introduce the various considerations required to develop a drug or device and offer general strategies for circumventing these hurdles.
Augie Diana, Ph.D., is a health scientist administrator at the NIH National Institute on Drug Abuse, where he oversees the SBIR/STTR grant portfolios for the Division of Epidemiology, Services and Prevention Research. Diana has over 25 years of experience conducting social research, including oversight of national, state and community evaluations at the Center for Substance Abuse Prevention, which is part of the federal Substance Abuse and Mental Health Services Administration, and at universities and in private industry in Boston and Colorado. Diana served as a member of the Inter-American Drug Abuse Control Commission workgroup that developed a compendium of prevention tools and measures, meant as a resource for local prevention program service providers. In addition, Diana has conducted extensive trainings for academic audiences, service providers and the larger community. Specific areas of expertise with regard to research, teaching and training include research methods, innovative methodological approaches, statistics, sport and leisure studies, crime and delinquency and substance abuse prevention.
Stephanie Fertig, M.B.A.
Stephanie J. Fertig, M.B.A, is the research project manager for small business programs in the Office of Translational Research at the NIH National Institute of Neurological Disorders and Stroke (NINDS). Fertig manages both the SBIR/STTR programs. Fertig joined NIH in 2004 as a member of the Repair and Plasticity cluster in the Division of Extramural Research at NINDS, where her primary scientific interests included neural engineering and neuroprosthesis, along with traumatic brain injury and spinal cord injury. In 2007, Fertig received an M.B.A. from the University of Maryland’s Robert H. Smith School of Business. Shortly after obtaining her degree, she started a detail working with the NINDS SBIR and STTR programs, which continued until her new position with the Institute in May 2010.
Before coming to NINDS, Fertig earned a B.S. in chemistry with a major in physics from the University of Virginia, Charlottesville. After completing her degree, she joined Nova Research, Inc. and worked as a researcher in the Center for Bio/Molecular Science and Engineering at the Naval Research Laboratory (NRL) in Washington D.C. At NRL she contributed to multiple bioengineering projects, including the development of molecular switches, benthic microbial fuel cells, microfluidics for use in biosensor applications and a wide variety of biosensor systems.
Edward Flynn, Ph.D., started Senior Scientific, LLC, to develop the concept of magnetic relaxometry for the detection and monitoring of cancer. Magnetic relaxometry combines the use of ultrasensitive magnetic sensors and special properties of magnetic nanoparticles, two technologies that rely on basic physics principles. After preliminary studies, Flynn applied for an SBIR grant in breast cancer and discovered the difficulty of presenting a completely new idea using basic physics principles to experts in the field of medicine and medical imaging. He found that it was necessary to learn the needs of the medical community and current technologies in order to demonstrate that magnetic relaxometry would have a substantial impact on cancer detection, while convincing medical imaging experts to think beyond their own fields.
After having success with Phase I SBIR funding, Flynn obtained Phase II funding and subsequent SBIR grants in ovarian cancer, leukemia and transplant rejection using the same methodology. Flynn formed collaborations with the University of New Mexico Health Sciences Center for cell and animal experiments and with the Center for Integrative Nanotechnology for producing advanced magnetic nanoparticles. The result was the development of an instrument with many orders of magnitude more sensitivity for detecting cancer. A preclinical instrument is now being manufactured and will be evaluated at MD Anderson Cancer Center.